Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAC Mechanisms in Cannabis Dependence
NCT03221231Phase 4Unknown
- Sponsor
- UZ Brussel
- Start
- May 2016
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of acetylcysteine in cannabis use disorder (CUD) (3 arms), sponsored by UZ Brussel. Primary endpoint: Brain glutamate concentrations in the anterior cingulate cortex at 2 weeks. Status: unknown.
02
Drugs
acetylcysteine
03
Conditions
cannabis use disorder (CUD)
Beyond the preview
Go deeper on NCT03221231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03221231.